Rockwood Wealth Management’s Foghorn Therapeutics FHTX Stock Holding History

Rockwood Wealth Management’s Portfolio FHTX Stock Details FHTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-107,329	Closed	-$392K	–	107
2025 Q1	$392K	Hold	107,329	–	–	0.04%	62
2024 Q4	$495K	Hold	107,329	–	–	0.05%	53
2024 Q3	$999K	Hold	107,329	–	–	0.11%	37
2024 Q2	$617K	Hold	107,329	–	–	0.08%	43
2024 Q1	$720K	Sell	107,329 -107,348	-50%	-$596K	0.09%	38
2023 Q4	$1.38M	Hold	214,677	–	–	0.2%	29
2023 Q3	$1.07M	Hold	214,677	–	–	0.18%	27
2023 Q2	$1.51M	Hold	214,677	–	–	0.26%	24
2023 Q1	$1.33M	Sell	214,677 -61,120	-22%	-$400K	0.26%	23
2022 Q4	$1.76M	Buy	275,797 +151,767	+122%	+$1.14M	0.41%	20
2022 Q3	$1.06M	Buy	+124,030	New	+$1.6M	0.34%	22

Other funds holding FHTX

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Rockwood Wealth Management's FHTX Position: Q2 2025 in Review

Rockwood Wealth Management sold out of Foghorn Therapeutics (FHTX) in Q2 2025, closing a stake of 107,329 shares — an estimated $392K sold.

Rockwood Wealth Management first reported a position in FHTX in Q3 2022 and held it in 11 quarters. The position peaked at $1.76M in Q4 2022. 81 funds tracked by Wall St. Rank hold FHTX as of Q2 2025.

Rockwood Wealth Management reported no remaining Foghorn Therapeutics position as of Q2 2025 after selling out during the quarter.
Rockwood Wealth Management sold 107,329 Foghorn Therapeutics shares in Q2 2025, an estimated $392K.
Rockwood Wealth Management first reported a position in Foghorn Therapeutics in Q3 2022 and held it in 11 quarters.
Rockwood Wealth Management's Foghorn Therapeutics position peaked at $1.76M in Q4 2022.
81 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q2 2025.

Based on Rockwood Wealth Management's 13F filing for Q2 2025, filed 11 Jul 2025.